《小细胞肺癌循环肿瘤细胞中PD-L1表达的评估》勘误
Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer.
出版信息
Transl Lung Cancer Res. 2022 May;11(5):950-952. doi: 10.21037/tlcr-2022-2.
Abstract
[This corrects the article DOI: 10.21037/tlcr-21-819.].
摘要
[本文更正了文章的数字对象标识符：10.21037/tlcr-21-819。]
相似文献
1
Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer.《小细胞肺癌循环肿瘤细胞中PD-L1表达的评估》勘误
Transl Lung Cancer Res. 2022 May;11(5):950-952. doi: 10.21037/tlcr-2022-2.
2
Erratum to cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.《转移性非小细胞肺癌患者接受PD-1/PD-L1抑制剂治疗的癌症恶病质综合征及临床结局：一项前瞻性观察性研究的结果》勘误
Transl Lung Cancer Res. 2023 Oct 31;12(10):2146-2147. doi: 10.21037/tlcr-2023-3. Epub 2023 Oct 20.
3
Erratum to efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis.《手术联合化疗治疗IIIA期小细胞肺癌患者的疗效评估：一项回顾性分析》勘误
Transl Lung Cancer Res. 2022 Dec;11(12):2610-2611. doi: 10.21037/tlcr-2022-9.
4
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.小细胞肺癌循环肿瘤细胞上程序性死亡受体配体1（PD-L1）表达的评估
Transl Lung Cancer Res. 2022 Mar;11(3):440-451. doi: 10.21037/tlcr-21-819.
5
Erratum: Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine.勘误：免疫治疗与精准医学时代局部晚期非小细胞肺癌患者的精准放疗。
Transl Lung Cancer Res. 2019 Aug;8(4):558. doi: 10.21037/tlcr.2019.04.11.
6
Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.《晚期非小细胞肺癌寡进展后立体定向体部放疗联合检查点抑制剂的勘误》
Transl Lung Cancer Res. 2022 Mar;11(3):504-505. doi: 10.21037/tlcr-2022-1.
7
Erratum: The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer.勘误：亚洲非小细胞肺癌患者中人类乳头瘤病毒感染与表皮生长因子受体突变之间的关联。
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S302. doi: 10.21037/tlcr.2018.07.14.
8
Erratum to tumor-associated macrophages secret exosomal miR-155 and miR-196a-5p to promote metastasis of non-small-cell lung cancer.《肿瘤相关巨噬细胞分泌外泌体miR-155和miR-196a-5p促进非小细胞肺癌转移》勘误
Transl Lung Cancer Res. 2021 Oct;10(10):4047-4048. doi: 10.21037/tlcr-2021-4.
9
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
10
Erratum to the importance of incorporating smoking cessation into lung cancer screening.《将戒烟纳入肺癌筛查的重要性》勘误
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S303. doi: 10.21037/tlcr.2018.09.02.
本文引用的文献
1
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.小细胞肺癌循环肿瘤细胞上程序性死亡受体配体1（PD-L1）表达的评估
Transl Lung Cancer Res. 2022 Mar;11(3):440-451. doi: 10.21037/tlcr-21-819.
Zotero 插件